The antimalarial drug presented through U.S. President Donald Trump as a COVID-19 remedy was useless for patients with a benign edition of the disease in an examination conducted by researchers at the University of Minnesota.
About 24% of patients who gained hydroxychloroquine on the test had persistent symptoms over a 14-day period, while approximately 30% of the placebo organization was decided to have persistent symptoms during the same period.
Read the latest updates in our coronavirus section. The difference is not statistically significant, the researchers said.
“Hydroxychloroquine has not particularly reduced the severity or prevalence of symptoms over time in other people not hospitalized with COVID-19 early,” the researchers wrote in an article to be published Thursday in annals of Internal Medicine.
A pharmacy technician pours hydroxychloroquine at Rock Canyon Pharmacy in Provo, Utah. (AFP)